India's Anthem Biosciences rises as Jefferies initiates coverage with 'buy' rating
BUZZ-India's Anthem Biosciences rises as Jefferies initiates coverage with 'buy' rating ** Drug research and manufacturing company Anthem Biosciences ANTH.NS shares rise as much as 2.3% to 894.90 rupees
** Jefferies initiates coverage with "Buy" rating and a PT of 1,050 rupees
** The PT represents a 20.1% upside to the stock's last close
** Brokerage expects Anthem to deliver strong revenue and profit growth over FY26-29, supported by its expanding business and project pipeline.
** Jefferies says growth should be supported by rising production of commercial products and a solid pipeline of projects in advanced stages of development
** ANTH trades at forward 12-month PE of 63.48 vs industry median of 26.95
** All of 8 brokerages covering the stock rate it "buy" or higher; their median PT is 900 rupees
** YTD, stock up 35.3%
(Reporting by Abhinav Parmar in Bengaluru)
Recent news on Anthem Biosciences
See all newsBrief: Anthem Biosciences Sept-Quarter Consol Profit 2.11 Billion Rupees
India's Anthem Biosciences rises as Jefferies initiates coverage with 'buy' rating
Brief: Anthem Biosciences June-Quarter Consol Profit 1.2 Billion Rupees
Brief: Anthem Biosciences March-Quarter Consol Profit 1.9 Bln Rupees
India's Anthem Biosciences rises after Citi starts with 'buy' rating